|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TANGO6 |
Gene summary for TANGO6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TANGO6 | Gene ID | 79613 |
| Gene name | transport and golgi organization 6 homolog | |
| Gene Alias | TMCO7 | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B3KTB6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79613 | TANGO6 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.12e-02 | 3.01e-01 | -0.2119 |
| 79613 | TANGO6 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 1.00e-02 | 6.17e-01 | -0.0263 |
| 79613 | TANGO6 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 3.50e-07 | 3.47e-01 | -0.0166 |
| 79613 | TANGO6 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 8.86e-10 | 3.82e-01 | -0.0132 |
| 79613 | TANGO6 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.48e-10 | 4.13e-01 | -0.013 |
| 79613 | TANGO6 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 7.85e-06 | 3.42e-01 | -0.0121 |
| 79613 | TANGO6 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 3.80e-03 | 4.60e-01 | -0.0961 |
| 79613 | TANGO6 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.49e-02 | 5.05e-01 | -0.0876 |
| 79613 | TANGO6 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 3.29e-04 | 5.20e-01 | -0.0822 |
| 79613 | TANGO6 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.56e-02 | 3.82e-01 | -0.0809 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TANGO6 | SNV | Missense_Mutation | c.2900N>C | p.Arg967Thr | p.R967T | Q9C0B7 | protein_coding | deleterious(0) | benign(0.031) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TANGO6 | SNV | Missense_Mutation | novel | c.1512N>T | p.Leu504Phe | p.L504F | Q9C0B7 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
| TANGO6 | SNV | Missense_Mutation | novel | c.2500N>A | p.Val834Ile | p.V834I | Q9C0B7 | protein_coding | tolerated(0.58) | benign(0) | TCGA-UL-AAZ6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | herceptin | SD |
| TANGO6 | insertion | Nonsense_Mutation | novel | c.2281_2282insAAGCCTTTGCTCCTTTGTCAAAGTTCAGTTGACTCTATT | p.Met761delinsLysAlaPheAlaProLeuSerLysPheSerTerLeuTyrLeu | p.M761delinsKAFAPLSKFS*LYL | Q9C0B7 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| TANGO6 | insertion | Frame_Shift_Ins | novel | c.1655_1656insTGCTGTTTCTTGGTCTCCAGCTGTTGGTCTTGCTGAGAGT | p.Lys552AsnfsTer18 | p.K552Nfs*18 | Q9C0B7 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| TANGO6 | insertion | Nonsense_Mutation | novel | c.2313_2314insTGCTGTTGTATTTAAAAGGTCATTG | p.Leu772CysfsTer5 | p.L772Cfs*5 | Q9C0B7 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| TANGO6 | SNV | Missense_Mutation | rs760746324 | c.11G>C | p.Arg4Pro | p.R4P | Q9C0B7 | protein_coding | tolerated_low_confidence(0.3) | benign(0) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| TANGO6 | SNV | Missense_Mutation | novel | c.1534N>A | p.Glu512Lys | p.E512K | Q9C0B7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| TANGO6 | SNV | Missense_Mutation | c.3046N>T | p.Arg1016Cys | p.R1016C | Q9C0B7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-C5-A2M2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TANGO6 | SNV | Missense_Mutation | novel | c.2966N>G | p.Asp989Gly | p.D989G | Q9C0B7 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-EA-A411-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |